NASDAQ$ZVRA
Zevra Therapeutics Inc · Q1 2021 earnings
Q1 2021 earnings · · Investor relations
Briefing
KemPharm's Q1 2021 financial results were reported, marked by significant achievements including FDA approval of AZSTARYS and a completed financial restructuring.
KemPharm reported a transformational first quarter of 2021 with the FDA approval of AZSTARYS, completion of financial restructuring, and re-listing on Nasdaq. The company reported revenue of $12.1 million and a net loss of $0.54 per share.
- AZSTARYS NDA was approved by the FDA on March 2, 2021.
- Amendment to Licensing Agreement with Gurnet Point Capital affiliate was announced following FDA approval of AZSTARYS.
- FDA clearance was received to initiate KP879 clinical program for the treatment of Stimulant Use Disorder.
- Serdexmethylphenidate (SDX) was classified as a Schedule IV Controlled Substance by the DEA.
Headline financials
Revenue & EPS history
Zevra · Revenue · Quarterly
$12.1M
Forward guidance
KemPharm has emerged from Q1 2021 as a Nasdaq-listed company with no debt and significant cash holdings on the balance sheet.
Tailwinds
- KemPharm has the resources needed to continue the development of KP879
- Significant cash holdings on the balance sheet
- No debt
- Evaluating how to efficiently deploy capital to generate additional value streams for shareholders.
- Creating long-term value is top of mind
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2021
-0.2%
Avg return
Earnings day
+0.0%
Avg return
5 days after
+3.8%
Avg return
30 days after
45%
20 / 44 earnings
Positive
+35.2%
Q2 2015
Best reaction
-19.4%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.0% | +1.6% | -0.1% | |
| Q4 2025 | +21.3% | +9.4% | +6.5% | |
| Q3 2025 | -9.8% | -6.4% | -13.5% | |
| Q1 2025 | +3.0% | +2.7% | +8.3% | |
| Q4 2024 | -2.1% | -2.1% | +10.5% | |
| Q3 2024 | -3.5% | -3.8% | -5.8% | |
| Q2 2024 | +2.6% | +8.2% | +11.5% | |
| Q1 2024 | -2.7% | -5.5% | -10.1% | |
| Q4 2023 | -13.3% | -13.9% | -23.9% | |
| Q3 2023 | -3.5% | -9.0% | +12.7% | |
| Q2 2023 | +3.8% | -4.2% | -2.7% | |
| Q1 2023 | +3.1% | +27.7% | +37.1% | |
| Q4 2022 | -19.4% | -22.8% | +4.9% | |
| Q3 2022 | -18.3% | -17.6% | -19.7% | |
| Q2 2022 | -5.4% | -14.6% | -4.3% | |
| Q1 2022 | +2.0% | +15.9% | +9.5% | |
| Q4 2021 | -4.7% | -1.3% | -15.3% | |
| Q3 2021 | -0.1% | -2.1% | -9.9% | |
| Q2 2021 | -9.4% | -7.2% | -7.6% | |
| Q1 2021 | +3.4% | +10.8% | +65.9% | |
| Q4 2020 | +19.5% | +14.4% | -8.3% | |
| Q3 2020 | -5.2% | +6.2% | +83.0% | |
| Q2 2020 | +8.7% | +46.8% | +48.9% | |
| Q1 2020 | -13.5% | -21.2% | -27.3% | |
| Q4 2019 | -0.9% | -8.5% | -30.9% | |
| Q3 2019 | +11.3% | -5.5% | -21.6% | |
| Q2 2019 | -15.8% | -18.3% | -25.8% | |
| Q1 2019 | +4.9% | +9.0% | +17.2% | |
| Q4 2018 | -14.6% | -16.2% | -32.4% | |
| Q3 2018 | -1.9% | -6.9% | +8.4% | |
| Q2 2018 | +5.5% | +0.0% | +13.7% | |
| Q1 2018 | +16.8% | +23.8% | +35.6% | |
| Q4 2017 | -9.9% | -13.2% | -29.1% | |
| Q3 2017 | +1.4% | +0.0% | +1.4% | |
| Q2 2017 | +8.5% | -8.5% | +9.3% | |
| Q1 2017 | +0.0% | +3.8% | +2.5% | |
| Q4 2016 | +9.7% | +18.1% | +31.9% | |
| Q3 2016 | +3.8% | +3.8% | -3.8% | |
| Q2 2016 | +0.0% | +7.7% | +22.0% | |
| Q1 2016 | -15.7% | — | — | |
| Q4 2015 | +0.7% | — | — | |
| Q3 2015 | -8.8% | — | — | |
| Q2 2015 | +35.2% | — | — | |
| Q1 2015 | -2.7% | — | — | |
| Q4 2014 | — | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro